Viking Therapeutics
  • Home
  • About
    • Overview
    • Management
    • Board of Directors
    • Careers
  • Pipeline
    • Overview
    • Metabolic Disease Programs
      • VK2809 (NASH)
      • VK2735 (Metabolic Disorders)
    • Rare Disease Program
      • VK0214 (X-ALD)
    • Other Pipeline Programs
      • VK5211 (Hip Fracture, Muscle Wasting)
      • VK0612 (Type 2 Diabetes)
      • VK1430 (Hypertriglyceridemia, NASH)
      • EPOR Agonist Program (Anemia)
  • Investors & Media
    • Overview
    • Stock Information
    • News & Events
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder Services
    • Corporate Presentation
  • Contact

    SEC Filings

    Investors

    • Overview
    • Stock Information
    • News & Events
    • SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Shareholder Services
    • Corporate Presentation

    NASDAQVKTX
    YearTrailing 12-MonthsCalendar Year 2023Calendar Year 2022Calendar Year 2021Calendar Year 2020Calendar Year 2019Calendar Year 2018Calendar Year 2017Calendar Year 2016Calendar Year 2015Calendar Year 2014
    ViewAll FilingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
    FormDescriptionDateFormat
    S-8Securities offered to employees pursuant to employee benefit plansFeb 10, 2023Open Securities offered to employees pursuant to employee benefit plans in HTML.Open Securities offered to employees pursuant to employee benefit plans in DOC file.Open Securities offered to employees pursuant to employee benefit plans in PDF file.Open Securities offered to employees pursuant to employee benefit plans in XLS file.

     

     

    viking therapeutics

    About

    Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.

    Contact

    General Information
    Business Development
    ©2023 Viking Therapeutics
    Terms of Use
    Privacy Policy